The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Vinflunine plus capecitabine for advanced breast cancer previously treated with or resistant to anthracycline and resistant to taxane: A phase III study versus capecitabine.
Matti S. Aapro
Consultant or Advisory Role - Pierre Fabre Medicament
Honoraria - Pierre Fabre Medicament
Research Funding - Pierre Fabre Medicament
Yuri Demidchik
No relevant relationships to disclose
Igor Bondarenko
No relevant relationships to disclose
Igor Siedakov
No relevant relationships to disclose
Dina Sakaeva
No relevant relationships to disclose
S. Krishnamurthy
No relevant relationships to disclose
Laslo Roman
No relevant relationships to disclose
Liudmila Lebedeva
No relevant relationships to disclose
Fawzia Mefti
No relevant relationships to disclose
Olga Ponomarova
No relevant relationships to disclose
Thomas Denis Bachelot
Consultant or Advisory Role - Roche
Research Funding - Roche
Iryna Lytvyn
No relevant relationships to disclose
Suzette Delaloge
No relevant relationships to disclose
Anita Kupp
No relevant relationships to disclose
Yauheniya Karchmit
No relevant relationships to disclose
Philippe Bougnoux
No relevant relationships to disclose
Mario Campone
Consultant or Advisory Role - Novartis; SERVIER
Honoraria - Novartis; SERVIER
Miguel Martin
No relevant relationships to disclose